The effect of new oral anticoagulants and extended thromboprophylaxis policy on hip and knee arthroplasty outcomes: observational study by Bottle, A et al.
lable at ScienceDirect
Arthroplasty Today 1 (2015) 45e50Contents lists avaiArthroplasty Today
journal homepage: http: / /www.arthroplastytoday.org/Original researchThe effect of new oral anticoagulants and extended
thromboprophylaxis policy on hip and knee arthroplasty outcomes:
observational study
Alex Bottle a, *, Emeka Oragui b, Elizabeth Pinder b, Paul Aylin a, Mark Loefﬂer b
a Department of Primary Care and Public Health, Dr Foster Unit at Imperial College London, London, UK
b Department of Orthopaedics, Colchester General Hospital, Colchester, Essex, UKa r t i c l e i n f o
Article history:
Received 8 January 2015
Received in revised form
26 February 2015
Accepted 2 March 2015





Administrative dataNo author associated with this paper has disclose
conﬂicts which may be perceived to have impending
full disclosure statements refer to http://dx.doi.org/10




2352-3441/Copyright © 2015 Published by Elsevier In
license (http://creativecommons.org/licenses/by-nc-na b s t r a c t
The efﬁcacy and safety of the new oral anticoagulants (NOAC) and the beneﬁts of extended duration
thromboprophylaxis following hip and knee replacements remain uncertain. This observational study
describes the relations between thromboprophylaxis policies following hip and knee replacements
across England's NHS and patient outcomes between January 2008 and December 2011. From the
national administrative database, we analyzed mortality, thromboembolic complications, emergency
readmission, and bleeding rates for 201,418 hip and 230,282 knee replacements. There were no differ-
ences in outcomes for either LMWH or NOAC. We found no advantage in favor of any single anti-
coagulation policy or in changing policy. This study supports the American Academy of Orthopaedic
Surgeons' recommendation that the choice and duration of thromboprophylaxis prophylaxis be decided
by the treating surgeon.
Copyright © 2015 Published by Elsevier Inc. on behalf of American Association of Hip and Knee Surgeons.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction frequent invasive monitoring due to their narrow therapeuticVenous thromboembolism (VTE) is a signiﬁcant, potentially fatal
complication that may occur in patients following total
knee arthroplasty (TKA) and total hip arthroplasty (THA). The
beneﬁts of providing pharmacological thromboprophylaxis in these
patients during their hospital admission have been established
[1] and are recommended by the American College of Chest Phy-
sicians [2] and the National Institute for Health and Clinical
Excellence (NICE) [3,4].
Historically, the options for short and extended duration
chemical thromboprophylaxis were limited to oral aspirin, vitamin
K antagonists such as warfarin, and low-molecular-weight heparin
(LMWH) preparations. Although LMWH has been shown to reduce
thromboembolic events, its route of administration by daily sub-
cutaneous injection may be associated with worse compliance and
may not be cost-effective [5]. In contrast, the orally administered
vitamin K antagonists, whilst having better compliance, required any potential or pertinent
conﬂict with this work. For
.1016/j.artd.2015.03.004.
EC4Y 8EN, UK. Tel.: þ44(0)
c. on behalf of American Associatio
d/4.0/).window [6,7].
The introduction of a new generation of oral anticoagulants
(NOAC) has combined the beneﬁts of both LMWH and warfarin.
Rivaroxaban (Bayer trade name Xarelto) and Apixaban
(Bristol-Myers Squibb: Eliquis) are direct oral inhibitors of factor Xa,
whereas Dabigatran (Boehringer Ingelheim: Pradaxa) inhibits
thrombin. Studies have shown them to be safe and effective, and
their ease of administration and lack of monitoring requirement
confer the additional beneﬁts of patient compliance and reduce the
need for invasivemonitoring. As a result, many studies and national
guidelines have recommended the use of NOAC in extended
VTE prophylaxis for 28e35 days after total hip arthroplasty and for
10e14 days after total knee arthroplasty [2,3,8e12].
Despite these guidelines, the evidence on the ideal duration for
all types of extended VTE prophylaxis is limited, and it is unclear
whether extended prophylaxis is associated with a signiﬁcant
reduction in morbidity or mortality [13]. Furthermore, it is unclear
whether NOAC are associated with lower mortality or morbidity
compared with the traditional agents.
The aim of this study was to address the key uncertainties in the
literature and in particular to answer the following questions:
1. What are the current thromboprophylaxis policies following
total hip and knee arthroplasty in NHS hospitals in England?n of Hip and Knee Surgeons. This is an open access article under the CC BY-NC-ND
A. Bottle et al. / Arthroplasty Today 1 (2015) 45e50462. Is there an association between the use of different thrombo-
prophylactic prescribing policies and patient morbidity and
mortality at 90 days and one year from surgery?
3. Does extended prophylaxis have any beneﬁt in reducing
morbidity or mortality in patients undergoing THA and TKA?
4. If a hospital changes its policy, will it also see changes in its rates
of morbidity and mortality?
5. Are NOAC safe?Material and methods
Thromboprophylactic policy
Using postal, email and telephonic questionnaires, we contacted
all acute National Health Service (NHS) hospital Trusts in England
regarding their VTE prophylactic policy for both hip and knee
replacement surgery between January 2008 and December 2011.
The questionnaire requested information about the presence or
absence of a Trust policy, the chemical agent used, and the duration
of use. We also requested information on any changes of policy
during that time period.
Patient records
From the national administrative database that covers all ad-
missions to NHS (public) hospitals in England, Hospital Episode
Statistics (HES), we extracted admissions for elective THA and TKA
between April 2008 andMarch 2012 using the Ofﬁce for Population
Censuses and Surveys Fourth Revision (OPCS4) primary procedure
codes W371, W381, W391, W931, W941, W951 (THA) and W401,
W411, W421 (TKA). The data set includes in-hospital deaths, age,
sex, postcode (allowing the area-level Carstairs deprivation quintile
to be added), 13 secondary diagnosis codes for co-morbidities and
complications (allowing the Charlson index of co-morbidity to be
derived using our version adapted for the NHS [14]) and 12 oper-
ation ﬁelds with dates. Patients who underwent surgery in Inde-
pendent Sector Treatment Centres (ISTCs) were excluded from the
analysis to reduce selection bias, as these patients tend to be
healthier, have less comorbidity and less severe primary hip and
knee pathology than the general NHS patient [15,16].
Outcome measures
We analyzed all-cause mortality in three ways: in-hospital, total
within 90 and total within 365 days from the operation date.
Unplanned all-cause hospital readmission, VTE and bleeding rates
at 90 days were established using the secondary diagnosis ﬁelds for
the index admission and the primary diagnosis for subsequent
admissions within 90 days of discharge following the operation. As
patients were clustered within hospitals, hierarchical logisticTable 1
Numbers of patients and numbers and crude rates of main 90-day outcomes by thromb










Heparin e standard 26,193 (6.1%)
Heparin e extended 160,794 (37.2%)
Total 431,700 (100%)regression models were ﬁtted, using SAS v9.2 PROC GLIMMIX,
adjusting for age, sex, year, comorbidity and deprivation. A number
of hospital trusts (organizations that can comprise more than one
site) changed their prescribing policy during the study period
(63 out of 111 for THA and 71 out of 105 Trusts for TKA). Some trusts
were unable to verify the exact date of policy change. Therefore, to
reduce misclassiﬁcation, we excluded from analysis all patient data
in the year where the policy change occurred.
Out of hospital deaths were available via linked ﬁles provided by
the Ofﬁce for National Statistics with complete dates of death until
the end of 2011. For our one-year mortality outcome, we therefore
had to exclude operations from 2010/1 onwards to allowone year of
follow-up.
We analyzed the 90-day mortality rates for those 37 hospitals
that changed from LMWH to NOAC. Hospitals that did not change
policy were also included in these models. Due to some national
temporal trends in outcome rates, a simple before versus after
comparison would have been misleading. Dummy variables to
indicate the year were included in the model, and an interaction
between policy group and time was ﬁtted. The question of interest
was whether hospitals that changed policy registered greater
(or lesser) improvements in their outcomes after changing than the
hospitals that did not change policy. In this too we excluded the
year of change due to hospitals' uncertainties over the date of policy
change.
P values of under 0.05 were considered statistically signiﬁcant.
Results
Study groups
From April 2008 through March 2012, 201,418 patients under-
going THA and 230,282 patients undergoing TKA were included.
More than two-thirds of patients were aged 65 or over; 60% were
female. 29.3% of THA and 33.1% of TKA patients had a non-zero
Charlson score.
Survey response rate
Details of the VTE policy for THA and TKA were obtained for
120 and 127 trusts respectively, giving a survey response rate of
80.5% and 86.4% respectively of all NHS Trusts. Of trusts who
responded to the survey, 63 out of 111 trusts (57%) reported a
change of prescribing policy for THA, whilst 71 out of 105 trusts
(68%) reported a change in policy for TKA during the study period.
Whilst the majority of trusts used heparin as their choice of VTE
prophylaxis following THA or TKA, by the end of the study a sig-
niﬁcant proportion of trusts had changed from using heparin to
NOAC. Aspirinwas the least frequently used agent at the start of the
study period; all six aspirin-using trusts switched to LMWH by the







51 (0.4%) 161 (1.4%) 5 (<0.1%)
389 (0.3%) 1451 (1.2%) 95 (0.1%)
206 (0.3%) 903 (1.1%) 71 (0.1%)
103 (0.3%) 546 (1.4%) 26 (0.1%)
113 (0.4%) 402 (1.4%) 17 (0.1%)
547 (0.3%) 2167 (1.5%) 129 (0.1%)
1409 (0.3%) 5630 (1.3%) 343 (0.1%)
Table 2
Adjusted odds ratios for each outcome by thromboprophylaxis policy group for THA (excluding calendar year of any policy change)
Policy In-hospital mortality 90d mortality 365d mortality 90d GI bleed 90d readmission 90d VTE
OR and CI p value OR and CI p value OR and CI p value OR and CI p value OR and CI p value OR and CI p value
Aspirin 0.60 (0.28e1.32) 0.207 0.93 (0.57e1.51) 0.756 1.32 (1.02e1.71) 0.036 0 (0e6.93) 0.895 1.01 (0.86e1.19) 0.873 0.88 (0.61e1.27) 0.505
Unknown (survey
non-responder)
1.00 (0.75e1.32) 0.974 1.00 (0.80e1.24) 0.968 0.93 (0.81e1.07) 0.329 1.07 (0.73e1.58) 0.729 1.03 (0.94e1.13) 0.488 0.91 (0.77e1.09) 0.313
NOAC 0.82 (0.54e1.25) 0.367 0.98 (0.68e1.41) 0.918 0.96 (0.67e1.39) 0.836 0.94 (0.54e1.62) 0.818 0.99 (0.91e1.07) 0.808 1.03 (0.84e1.25) 0.805
Variablea 0.82 (0.49e1.36) 0.443 0.72 (0.48e1.09) 0.118 0.86 (0.66e1.13) 0.277 0.98 (0.50e1.93) 0.956 0.94 (0.84e1.05) 0.276 1.16 (0.91e1.49) 0.223
Heparin e standard 0.81 (0.51e1.29) 0.379 0.93 (0.67e1.29) 0.670 0.90 (0.73e1.10) 0.283 0.89 (0.44e1.81) 0.746 1.00 (0.90e1.11) 0.966 1.17 (0.93e1.46) 0.183
Heparin e extended 1 1 1 1 1 1
Bold indicates p < 0.05.
NOAC ¼ new oral anticoagulants.
a Surgeon-speciﬁc within the hospital.
Table 3
Adjusted odds ratios for each outcome by thromboprophylaxis policy for TKA (excluding calendar year of any policy change)
policy In-hospital mortality 90d mortality 365d mortality 90d GI bleed 90d readmission 90d VTE
OR and CI p value OR and CI p value OR and CI p value OR and CI p value OR and CI p value OR and CI p value
Aspirin 1.15 (0.60e2.20) 0.667 1.14 (0.74e1.75) 0.566 1.08 (0.79e1.49) 0.625 1.13 (0.43e2.98) 0.810 1.05 (0.90e1.21) 0.546 1.12 (0.80e1.57) 0.519
Unknown (survey
non-responder)
0.85 (0.63e1.15) 0.302 0.93 (0.76e1.14) 0.504 1.02 (0.88e1.19) 0.771 1.10 (0.73e1.67) 0.639 0.97 (0.90e1.05) 0.448 0.92 (0.77e1.10) 0.347
NOAC 1.03 (0.69e1.53) 0.901 1.24 (0.88e1.74) 0.213 1.16 (0.79e1.70) 0.441 1.16 (0.65e2.07) 0.614 1.04 (0.97e1.12) 0.278 1.06 (0.90e1.26) 0.481
Variablea 0.86 (0.52e1.43) 0.569 0.79 (0.51e1.23) 0.298 0.90 (0.62e1.31) 0.583 1.20 (0.60e2.42) 0.607 0.99 (0.90e1.10) 0.921 0.99 (0.79e1.25) 0.943
Heparin - standard 1.20 (0.78e1.85) 0.405 1.05 (0.77e1.43) 0.774 1.09 (0.88e1.34) 0.426 0.70 (0.32e1.53) 0.373 0.92 (0.83e1.01) 0.089 0.97 (0.78e1.21) 0.805
Heparin -extended 1 1 1 1 1 1
NOAC ¼ new oral anticoagulants.















Adjusted odds ratios for each outcome for in-patient heparin compared with extended duration for heparin or new oral anticoagulants, following THA or TKA
Outcome Measure THA TKA
Heparin IP Heparin or
NOAC
extended
Heparin IP Heparin or
NOAC
extended
In-hospital mortality OR (95% CI) 0.81 (0.51e1.27) 1 1.22 (0.80e1.86) 1
p value 0.348 0.366
90d mortality OR (95% CI) 0.95 (0.69e1.30) 1 1.00 (0.73e1.37) 1
p value 0.733 0.994
365d mortality OR (95% CI) 0.92 (0.76e1.12) 1 1.07 (0.88e1.30) 1
p value 0.403 0.513
90d GI bleed OR (95% CI) 0.78 (0.39e1.56) 1 0.65 (0.30e1.40) 1
p value 0.485 0.269
90d Readmission OR (95% CI) 1.01 (0.91e1.11) 1 0.93 (0.85e1.02) 1
p value 0.865 0.131
90d VTE OR (95% CI) 1.18 (0.95e1.47) 1 1.02 (0.84e1.25) 1
p value 0.132 0.823
NOAC ¼ new oral anticoagulants.
A. Bottle et al. / Arthroplasty Today 1 (2015) 45e5048Mortality and VTE rates
90-day crude rates for total mortality and coded VTE and
GI bleed were low (Table 1). The in-hospital mortality rate was
0.2% after both procedures, and the total 365-day mortality rate
was 0.8% for THA and 0.6% for TKA. 9.0% of THA patients and 9.4% of
TKA patients were readmitted within 90 days.
The covariate-adjusted outcome rates by policy for the THA and
TKA groups are presented in Tables 2 and 3. For THA, in-hospital
mortality, 90-day mortality and 90-day VTE rates did not differ
signiﬁcantly between the different policy groups. The 365-day
mortality rate in the small aspirin group following THA was
signiﬁcantly higher than in any other group undergoing
THA (p ¼ 0.036) with OR of 1.32 (1.02e1.71). Analysis for TKA did
not show any statistically signiﬁcant difference between mortality
rates and VTE rates for different policy groups.Hemorrhagic complications and readmissions
The recorded rate of GI bleeding within 90 days and all-cause
readmission within 90 days did not differ signiﬁcantly between
different policy groups for either THA or TKA.Sensitivity analysis for the timing of policy change
As mentioned above, around two-thirds of trusts changed their
policy during the period. By excluding the year of change in our
primary analysis and reduce the likelihood of misclassifying the
policy group, statistical power is reduced. Therefore, a sensitivity
analysis was performed by including all patients in the study and
assuming that any change in prescribing policy occurred in January
of that year. Results were similar to those after excluding the year of
change. The only statistically signiﬁcant difference in outcomesTable 5
Adjusted odds ratios for 90-day mortality for a thromboprophylaxis policy change
from heparin standard or heparin extended to new oral anticoagulants
Policy change THA TKA
Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Heparin standard
to NOAC
1.27 (0.87e1.86) 0.215 1.43 (1.00e2.03) 0.049
Heprain extended
to NOAC
0.84 (0.58e1.21) 0.064 0.97 (0.74e1.26) 0.806
NOAC ¼ new oral anticoagulants.between different policy groups was an increase in the 365-day
mortality in the aspirin group following THA (p ¼ 0.018) with
OR of 1.36 (1.05e1.75).
Extended prophylaxis
We compared the outcomes of Trusts using LMWH during the
in-patient period only with Trusts who used either LMWH or NOAC
in extended duration (Table 4). For THA and TKA, no statistically
signiﬁcant difference was found between the mortality, read-
mission, GI bleeding and VTE rates of the different policy groups.
Changing policy
We looked at whether a change in prescribing policy led to a
change in outcomes. We observed some temporal trends in
outcome measure over the period of the study for different policy
groups. Therefore, we compared the change in outcomes for hos-
pitals that changed their policy from standard or extended
LMWH to NOAC with hospitals that did not change their policy of
LMWH (Table 5). Wewere restricted by small numbers of outcomes
in this hospital subset to analyzing the change in 90-day mortality
rates. Changing from standard duration LMWH to NOAC was
associated with a non-signiﬁcant increase in 90-day mortality rates
in the TKA group, and the conﬁdence interval was wide.
Discussion
The aim of this study was to survey the current thrombopro-
phylaxis policies following total hip and knee arthroplasty in
NHS hospitals in England and to determine whether there was any
association between the use of different policies and patient out-
comes with respect to morbidity and mortality outcomes. We
found that the efﬁcacy and safety of LMWH and NOAC were com-
parable irrespective of their duration of use and that a change in
policy did not lead to a demonstrable change in mortality or
morbidity rates. We now consider each study question in turn.
What are the current thromboprophylaxis policies following total
hip and knee arthroplasty in NHS hospitals in England?
This study highlights the current prophylactic regimes of all
hospital trusts in England over a four-year period with a sample of
over 400,000 patients. The vast majority of trusts have a policy in
place, but there are also a signiﬁcant number of trusts where the
A. Bottle et al. / Arthroplasty Today 1 (2015) 45e50 49treatment is down to individual surgeon preference. The most
common pharmacological agent used was LMWH. 71 trusts
changed their prescribing policy during the period studied
(the majority to NOAC), likely in response to the introduction of
NICE clinical practice guidelines.
Is there an association between the use of different
thromboprophylactic prescribing policies and patient morbidity and
mortality at 90 days and one year from surgery?
In our study we found no evidence to support NOAC superiority
over LMWH following THA and TKA. Most of the studies that have
been able to show a beneﬁt in the use of NOAC have been
pharmaceutical-sponsored studies that used a venographic tech-
nique to detect asymptomatic VTE. In the RE-MODEL, RE-NOVATE
AND RE-NOVATE II trials [8,9,17], dabigatran was shown to be non-
inferior to enoxaparin in preventing VTE and in all-cause mortality,
whereas pooled analysis of patients from four RECORD phase II
clinical trials showed Rivaroxaban to be superior to Enoxaparin in
reducing symptomatic DVT and all-cause mortality [18]. However,
in clinical practice ultrasonography is more commonly used to
conﬁrm the diagnosis of clinically apparent VTE, and it is not certain
whether a reduction in asymptomatic VTE correlates with
improved patient outcomes. Parvizi et al. have questioned the
correlation of asymptomatic DVT with symptomatic PE and found
the relationship to be negligible [19]. Our ﬁndings suggest that any
reported beneﬁts of NOAC observed in these trials may be not
borne out in clinical practice on a large scale.
Does extended prophylaxis or a change in policy to extended
prophylaxis reduce morbidity and mortality in patients undergoing
THA and TKA?
With the recent trend towards extended VTE prophylaxis
[20,21], the beneﬁts of such a policy have been called into question.
Husted et al. found their rates of VTE with a standard regime were
comparable to series using an extended regime and cautioned
against the indiscriminate use of an extended VTE prophylaxis
policy [13].
Our study showed that the type of prophylaxis used and the
duration of treatment had no effect on outcomes following THA or
TKA. Furthermore, for those trusts that changed their prescribing
policy from a standard to an extended duration, there was no dif-
ference in 90-day mortality rates after the change in policy.
Are NOAC safe?
There have been concerns from the orthopadic community that
NOAC may be associated with an increased bleeding risk compared
with traditional agents. In a systematic review and meta-analysis,
Gomez et al. compared the use of LMWH with Rivaroxaban
following THA and TKA and concluded that the relative risk of
bleeding was higher with the NOAC [22]. Marlow et al. reported
similarﬁndings in 2011, albeitwith a small study [23]. Surgeonsmay
also bewary of these anticoagulants, as theyare not easily reversible
compared with LMWH and warfarin. In an analysis of prospectively
collected data on English hospital trusts, Jameson et al. reported a
signiﬁcantly higher rate of wound complications with Rivaroxaban
comparedwith LMWH following THA or TKA, with no differences in
symptomatic pulmonary emboli or mortality [24].
In 2011, both the UK Department of Health [25] and the United
States Centers for Medicare and Medicaid Services [26] imple-
mented a 30-day all-cause readmission penalty following THA and
TKA. Thus the identiﬁcation of anticoagulants that are associated
with a reduced bleeding risk and a reduced readmission rate is animportant area in optimizing patient outcomes and minimizing the
economic burden of these complications to the treating hospital.
Our study found that the use of LMWH and NOAC was compa-
rable in terms of 90-day bleeding rates and 90-day readmission
rates for all causes. The mechanism of action of all chemical
thromboprophylaxis agents is likely to cause hematomas and
extended bleeding from surgical wounds. We did not have infor-
mation on wound complications, and it is possible that our out-
comes were not sensitive enough to detect speciﬁc complications
associated with NOAC use. However, a policy of using NOACs as
chemical thromboprophylaxis was not associated with signiﬁcantly
higher readmission or mortality rates, suggesting that the use
of NOACs for chemical thromboprophylaxis in hip and knee
replacements is as safe as other anticoagulants.
Strengths and limitations of the study
The study beneﬁts from a large sample size (over 400,000
patients). It had an excellent response rate for the survey, and the
fact that the non-response group had similar outcomes to the rest
suggests, though cannot prove, that the effect of non-responder
bias is small.
The reliability of the HES database is dependent on the accuracy
of coding, which is good and improving [27,28]. This database is
more accurate when analyzed for hard end points such as mortality
and all-cause readmission, but less reliable for secondary diagnoses
such as VTE and bleeding if variation in the quality of coding exists.
We found 90-day rates of recorded VTE of 1.1% for THA and 1.5% for
TKA; our recorded GI bleed rates were 0.1% for both. By comparison,
the Global Orthopaedic Registry, containing 15,000 procedures in
three years up to 2004 in 13 countries, reported 90-day VTE rates of
0.9% for THA and 1.3% for TKA and 90-day GI bleed rates for 0.1% for
THA and 0.2% for TKA [29]. These ﬁgures are very similar to ours.
We had limited numbers of events to assess the effect on out-
comes when hospitals changed policy and were restricted to
considering 90-day mortality. While important, this outcome is
much less sensitive than morbidity measures to the effects of
changing practice. Regarding outcomes, we chose to use VTE rather
than just PE because, while PE is the more important complication
than symptomatic DVT, both are complications that thrombopro-
phylaxis should reduce so it is more relevant to use both as an
endpoint.
A limitation of our survey is that the presence of a hospital
policy does not necessarily equate to full compliance in clinical
practice across the hospital [30]. However, this data set shows the
link between the stated policy of the hospital and the outcome and
is thereby akin to an intention-to-treat analysis, which is standard
in clinical trials. A second limitation is that we do not have data on
hospital policies on mechanical thromboprophylaxis or on post-
operative ultrasonography use. Finally, HES data do not capture
activity in primary care, and by only capturing conditions serious
enough to warrant readmission, our data may under-estimate the
morbidity associated with different prescribing policies. However,
we would not expect there to be a relation between policy group
and recording levels. It therefore seems unlikely that a bias exists
when comparing the outcomes between different policies, though
this cannot be ruled out.
Conclusions
This national study reﬂects recent clinical practice by surgeons
across England. Despite clinical practice guidelines advocating the
use of extended chemical prophylaxis for joint replacement
surgery, we have found no evidence to support this practice.
The efﬁcacy and safety of LMWH and NOAC were found to be
A. Bottle et al. / Arthroplasty Today 1 (2015) 45e5050comparable irrespective of their duration of use. This study would
support the American Academy of Orthopaedic Surgeons' recom-
mendation [31] that the overriding choice and duration of pro-
phylaxis be decided by the treating physician on an individual basis.
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